Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Using mfn2 Knockout Zebrafish as a Novel Model of ALS
Neuromuscular and Clinical Neurophysiology (EMG)
S11 - ALS and Motor Neuron Disorders (2:24 PM-2:36 PM)
008

BACKGROUND: ALS is a rapidly fatal, rare neurodegenerative disease typified by the loss of motor neurons in the motor cortex and spinal cord. Twin studies estimate the heritability of sporadic ALS (SALS) to be 61%, yet mutations in known mendelian ALS genes only account for 17% of SALS cases. MFN2 is a mitochondrial outer membrane protein and mitochondrial function is implicated in ALS pathology. Zebrafish have been used previously to model motor neuron disease.

To better understand amyotrophic lateral sclerosis (ALS), we used sequence data from patients to identify novel disease-associated loci and in vivo studies to determine the biological effect of loss of Mitofusin 2 (MFN2) function in zebrafish.

DESIGN/METHODS: Sequencing data for 140 ALS patients were analyzed using VAAST and Phevor to identify genes burdened with rare, nonsynonymous variants. MFN2 was a top hit. We analyzed mfn2 knockout (KO) zebrafish, including movement assays and TDP-43 levels in brain lysates.

RESULTS:  We found a disproportionate burden of MFN2 mutations in SALS cases. mfn2 heterozygote and homozygous KO zebrafish displayed movement deficits, and abnormal spine morphology.  In addition, mfn2 KO zebrafish showed increased levels of TDP-43 and lower molecular weight TDP-43 isoforms from cerebellum/hindbrain lysates

CONCLUSIONS: We identified MFN2 as a potential SALS-associated gene. In vivo zebrafish studies show motor and spine morphology consistent with known ALS phenotypes in zebrafish, as well as abnormal accumulation of TDP-43 in their brains.  Interestingly, MFN2 is a known cause of Charcot-Marie-Tooth Type 2A (CMT2A). We hypothesize that CMT2A and ALS are on a disease spectrum, and that MFN2 is a novel modifier of ALS pathology.

Authors/Disclosures
Kristi Russell, PhD (University of Utah EIHG)
PRESENTER
The institution of Mrs. Russell has received research support from Margolis Foundation.
Jon Downie, PhD (University of Utah - Department of Human Genetics) Dr. Downie has nothing to disclose.
Summer Gibson, MD An immediate family member of Dr. Gibson has received personal compensation for serving as an employee of Recursion Pharmaceuticals. Dr. Gibson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. An immediate family member of Dr. Gibson has received stock or an ownership interest from Recursion Pharmaceuticals . An immediate family member of Dr. Gibson has received intellectual property interests from a discovery or technology relating to health care. Dr. Gibson has received publishing royalties from a publication relating to health care.
Karla P. Figueroa (University of Utah) Ms. Figueroa has nothing to disclose.
Mark B. Bromberg, MD, PhD, FAAN (University of Utah) Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health. Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics. Dr. Bromberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Bromberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT Pharma. Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Grifols. Dr. Bromberg has received publishing royalties from a publication relating to health care. Dr. Bromberg has received publishing royalties from a publication relating to health care. Dr. Bromberg has received publishing royalties from a publication relating to health care. Dr. Bromberg has received personal compensation in the range of $5,000-$9,999 for serving as a Medical reviewer with Department of Justice, Vaccination Compensation Board.
Joshua Bonkowsky, MD, PhD Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Passage Bio. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Bonkowsky has stock in Orchard. The institution of Dr. Bonkowsky has received research support from NIH. The institution of Dr. Bonkowsky has received research support from ELA. An immediate family member of Dr. Bonkowsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Bonkowsky has received publishing royalties from a publication relating to health care. Dr. Bonkowsky has received publishing royalties from a publication relating to health care.
No disclosure on file
Stefan M. Pulst, MD, FAAN (University of Utah) Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care.